))
GET REAL: A Guide to Evolving Treatment of nAMD and DME Using Real-World Data
Manage episode 414417315 series 3381434
Treść dostarczona przez ReachMD. Cała zawartość podcastów, w tym odcinki, grafika i opisy podcastów, jest przesyłana i udostępniana bezpośrednio przez ReachMD lub jego partnera na platformie podcastów. Jeśli uważasz, że ktoś wykorzystuje Twoje dzieło chronione prawem autorskim bez Twojej zgody, możesz postępować zgodnie z procedurą opisaną tutaj https://pl.player.fm/legal.
CME credits: 1.00
Valid until: 02-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/get-real-a-guide-to-evolving-treatment-of-namd-and-dme-using-real-world-data/16619/
Let’s get real. Clinical trial data can be difficult to apply to retina practices. Patient populations are often limited, and injection schedules are strictly enforced in clinical trial settings. Fortunately, real-world evidence based on large registry data are amassing to shed light on current treatment practices and their effects on patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Join our expert faculty as they reveal real-world experience with anti-vascular endothelial growth factor (VEGF) therapy and novel dual inhibition therapy and assess how this information might be used to guide practice changes.=
…
continue reading
Valid until: 02-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/get-real-a-guide-to-evolving-treatment-of-namd-and-dme-using-real-world-data/16619/
Let’s get real. Clinical trial data can be difficult to apply to retina practices. Patient populations are often limited, and injection schedules are strictly enforced in clinical trial settings. Fortunately, real-world evidence based on large registry data are amassing to shed light on current treatment practices and their effects on patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Join our expert faculty as they reveal real-world experience with anti-vascular endothelial growth factor (VEGF) therapy and novel dual inhibition therapy and assess how this information might be used to guide practice changes.=
659 odcinków
Udostępnij
